LY 3839840
Alternative Names: LY-3839840; SYX-1042Latest Information Update: 15 Dec 2023
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 04 Dec 2023 Eli Lilly and Company plans a first-in-human phase I trial (In volunteers) in USA (PO) in December 2023 (NCT06153355)
- 01 Dec 2023 Preclinical trials in Autoimmune disorders in USA (PO)